Human cytomegalovirus infection and antiviral immunity in septic patients without canonical immunosuppression

Medical Microbiology and Immunology

Volumn 197, Issue 2, 2008, Pages 75-82

  Von Müller, Lutz ^a,b   Mertens, Thomas ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Cytomegalovirus; Disease; Immunity; Latency; Reactivation; Sepsis; Therapy

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR;

ADAPTIVE IMMUNITY; ANTIVIRAL THERAPY; ARTIFICIAL VENTILATION; CELLULAR IMMUNITY; CYTOMEGALOVIRUS INFECTION; HELPER CELL; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INNATE IMMUNITY; INTENSIVE CARE UNIT; LENGTH OF STAY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REINFECTION; REVIEW; SEPTIC SHOCK; T LYMPHOCYTE; VIRUS CELL INTERACTION; VIRUS LATENCY; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; KILLER CELLS, NATURAL; SHOCK, SEPTIC; T-LYMPHOCYTES; VIRUS ACTIVATION;

EID: 42249092074     PISSN: 03008584     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00430-008-0087-0     Document Type: Review

References (55)

1. Stagno S, Britt W (2006) Cytomegalovirus infections. In: Remington JS, Klein JO, Wilson CB, Baker CJ (eds) Infectious diseases of the fetus and newborn infant, 6th edn. Elsevier Saunders, Philadelphia, pp 739-781
2. Griffiths PD (2002) Tomorrow's challenges for herpesvirus management: potential applications of valacyclovir. J Infect Dis 186(Suppl 1):S131-S137
3. Ljungman P, Griffiths P, Paya C (2002) Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34:1094-1097
4. Sinclair J, Sissons P (2006) Latency and reactivation of human cytomegalovirus. J Gen Virol 87:1763-1779
5. Hummel M, Abecassis MM (2002) A model for reactivation of CMV from latency. J Clin Virol 25(Suppl 2):S123-S136
6. Simon CO, Seckert CK, Dreis D, Reddehase MJ, Grzimek NK (2005) Role for tumor necrosis factor alpha in murine cytomegalovirus transcriptional reactivation in latently infected lungs. J Virol 79:326-340
7. Boeckh M, Boivin G (1998) Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol Rev 11:533-554
8. von Müller L, Klemm A, Weiss M, Schneider M, Suger-Wiedeck H, Durmus N, Hampl W, Mertens T (2006) Active cytomegalovirus infection in patients with septic shock. Emerg Infect Dis 12:1517-1522
9. Heininger A, Jahn G, Engel C, Notheisen T, Unertl K, Hamprecht K (2001) Human cytomegalovirus infections in nonimmunosuppressed critically ill patients. Crit Care Med 29:541-547
10. Kutza AST, Muhl E, Hackstein H, Kirchner H, Bein G (1998) High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis 26:1076-1082
11. Limaye AP, Kirby KA, Rubenfeld GD, Huang ML, Santo TK, Corey L, Boeckh M (2007) Association of cytomegalovirus (CMV) viral load with intensive care unit and hospital length of stay in critically-ill immunocompetent patients. Abstract #406, American Thoracic Society international Conference
12. Mocarski ES, Shenk T, Pass RF (2007) Cytomegalovirus. In: Knipe DM, Howley PM (eds) Fields virology, 5th edn. Lippincott-Raven, Philadelphia, pp 2701-2772
13. von Müller L, Klemm A, Durmus N, Weiss M, Suger-Wiedeck H, Schneider M, Hampl W, Mertens T (2007) Cellular immunity and active human cytomegalovirus infection in patients with septic shock. J Infect Dis 196:1288-1295
14. Frascaroli G, Varani S, Mastroianni A, Britton S, Gibellini D, Rossini G, Landini MP, Soderberg-Naucler C (2006) Dendritic cell function in cytomegalovirus-infected patients with mononucleosis. J Leukoc Biol 79:932-940
15. Ljungman P, Reusser P, de la CR, Einsele H, Engelhard D, Ribaud P, Ward K (2004) Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant 33:1075-1081
16. Barrios Y, Knor S, Lantto J, Mach M, Ohlin M (2007) Clonal repertoire diversification of a neutralizing cytomegalovirus glycoprotein B-specific antibody results in variants with diverse anti-viral properties. Mol Immunol 44:680-690
17. Nigro G, Adler SP, La TR, Best AM (2005) Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353:1350-1362
18. Klenovsek K, Weisel F, Schneider A, Appelt U, Jonjic S, Messerle M, Bradel-Tretheway B, Winkler TH, Mach M (2007) Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells. Blood 110:3472-3479
19. Reddehase MJ, Jonjic S, Weiland F, Mutter W, Koszinowski UH (1988) Adoptive immunotherapy of murine cytomegalovirus adrenalitis in the immunocompromised host: CD4-helper-independent antiviral function of CD8-positive memory T lymphocytes derived from latently infected donors. J Virol 62:1061-1065
20. Hertenstein B, Hampl W, Bunjes D, Wiesneth M, Duncker C, Koszinowski U, Heimpel H, Arnold R, Mertens Th (1995) In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transplant 15:387-393
21. Cerboni C, Mousavi-Jazi M, Linde A, Söderström K, Brytting M, Wahren B, Kärre K, Carbone E (2000) Human cytomegalovirus strain-dependent changes in NK cell recognition of infected fibroblasts. J Immunol 164:4775-4782
22. Reddehase MJ, Balthesen M, Rapp M, Jonjic S, Pavic I, Koszinowski UH (1994) The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. J Exp Med 179:185-193
23. Slobedman B, Mocarski ES (1999) Quantitative analysis of latent human cytomegalovirus. J Virol 73:4806-4812
24. Steffens H-P, Kurz S, Holtappels R, Reddehase MJ (1998) Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence. J Virol 72:1797-1804
25. Hummel M, Zhang Z, Yan S, DePlaen I, Golia P, Varghese T, Thomas G, Abecassis MI (2001) Allogeneic transplantation induces expression of cytomegalovirus immediate-early genes in vivo: a model for reactivation from latency. J Virol 75:4814-4822
26. Cook CH, Zhang Y, McGuinness BJ, Lahm MC, Sedmak DD, Ferguson RM (2002) Intra-abdominal bacterial infection reactivates latent pulmonary cytomegalovirus in immunocompetent mice. J Infect Dis 185:1395-1400
27. Cook CH, Trgovcich J, Zimmerman PD, Zhang Y, Sedmak DD (2006) Lipopolysaccharide, tumor necrosis factor alpha, or interleukin-1beta triggers reactivation of latent cytomegalovirus in immunocompetent mice. J Virol 80:9151-9158
28. von Müller L, Schliep C, Storck M, Hampl W, Schmid T, Abendroth D, Mertens T (2006) Severe graft rejection, increased immunosuppression, and active CMV infection in renal transplantation. J Med Virol 78:394-399
29. Reeves MB, MacAry PA, Lehner PJ, Sissons JG, Sinclair JH (2005) Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers. Proc Natl Acad Sci USA 102:4140-4145
30. Reeves MB, Coleman H, Chadderton J, Goddard M, Sissons JG, Sinclair JH (2004) Vascular endothelial and smooth muscle cells are unlikely to be major sites of latency of human cytomegalovirus in vivo. J Gen Virol 85:3337-3341
31. Mocarski ES (2002) Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbiol 10:332-339
32. Soderberg-Naucler C, Fish KN, Nelson JA (1997) Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 91:119-126
33. Rennekampff HO, Hamprecht K (2006) Cytomegalovirus infection in burns: a review. J Med Microbiol 55:483-487
34. Sester M, Gartner BC, Sester U, Girndt M, Mueller-Lantzsch N, Kohler H (2003) Is the cytomegalovirus serologic status always accurate? a comparative analysis of humoral and cellular immunity. Transplantation 76:1229-1230
35. von Müller L, Hinz J, Bommer M, Hampl W, Kluwick S, Wiedmann M, Bunjes D, Mertens T (2007) CMV monitoring using blood cells and plasma: a comparison of apples with oranges? Bone Marrow Transplant 39:353-357
36. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD (2000) Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 355:2032-2036
37. Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J, Grigoleit U, Moris A, Rammensee HG, Kanz L et al (2002) Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99:3916-3922
38. Fishman JA (2007) Infection in solid-organ transplant recipients. N Engl J Med 357:2601-2614
39. Rauser G, Einsele H, Sinzger C, Wernet D, Kuntz G, Assenmacher M, Campbell JD, Topp MS (2004) Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood 103:3565-3572
40. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD (1992) Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257:238-241
41. Mocarski ES (2004) Immune escape and exploitation strategies of cytomegaloviruses: impact on and imitation of the major histocompatibility system. Cell Microbiol 6:707-717
42. French AR, Yokoyama WM (2003) Natural killer cells and viral infections. Curr Opin Immunol 15:45-51
43. Puente J, Carvajal T, Parra S, Miranda D, Sepulveda C, Wolf ME, Mosnaim AD (1993) In vitro studies of natural killer cell activity in septic shock patients. Response to a challenge with alpha-interferon and interleukin-2. Int J Clin Pharmacol Ther Toxicol 31:271-275
44. Vredevoe DL, Widawski M, Fonarow GC, Hamilton M, Martinez-Maza O, Gage JR (2004) Interleukin-6 (IL-6) expression and natural killer (NK) cell dysfunction and anergy in heart failure. Am J Cardiol 93:1007-1011
45. Waner JL, Budnick JE (1977) Blastogenic response of human lymphocytes to human cytomegalovirus. Clin Exp Immunol 30:44-49
46. Sester M, Sester U, Gärtner B, Heine G, Girndt M, Mueller-Lantzsch N, Meyerhans A, Kohler H (2001) Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 71:1287-1294
47. Llewelyn M, Cohen J (2002) Superantigens: microbial agents that corrupt immunity. Lancet Infect Dis 2:156-162
48. Ljungman P, De Bock R, Cordonnier C, Einsele H, Engelhard D, Grundy J, Locasciulli A, Reusser P, Ribaud P (1993) Practices for cytomegalovirus diagnosis, prophylaxis and treatment in allogeneic bone marrow transplant recipients: a report from the working party for infectious diseases of the EBMT. Bone Marrow Transplant 12:399-403
49. Barry SM, Johnson MA, Janossy G (2000) Cytopathology or immunopathology? The puzzle of cytomegalovirus pneumonitis revisited. Bone Marrow Transplant 26:591-597
50. Fishman JA, Emery V, Freeman R, Pascual M, Rostaing L, Schlitt HJ, Sgarabotto D, Torre-Cisneros J, Uknis ME (2007) Cytomegalovirus in transplantation-challenging the status quo. Clin Transplant 21:149-158
51. Lowance D, Neumayer H-H, Legendre CM, Squifflet J-P, Kovarik J, Brennan PJ, Norman D, Mendez R, Keating MR, Coggon GL et al (1999) Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 340:1462-1470
52. Reinhardt B, Mertens Th, Mayr U, Frank H, Lüske A, Waltenberger J (2004) HCMV-infection leads to enhanced PDGF responsiveness of vascular smooth muscle cells. Cardiovasc Res
53. Cook CH, Zhang Y, Sedmak DD, Martin LC, Jewell S, Ferguson RM (2006) Pulmonary cytomegalovirus reactivation causes pathology in immunocompetent mice. Crit Care Med 34:842-849
54. Docke WD, Prosch S, Fietze E, Kimel V, Zuckermann H, Klug C, Syrbe U, Kruger DH, von Baehr R, Volk HD (1994) Cytomegalovirus reactivation and tumour necrosis factor. Lancet 343:268-269
55. Simon CO, Holtappels R, Tervo HM, Bohm V, Daubner T, Oehrlein-Karpi SA, Kuhnapfel B, Renzaho A, Strand D, Podlech J et al (2006) CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation. J Virol 80:10436-10456